Literature DB >> 12202865

Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors.

Masaki Tomita1, Yasunori Matsuzaki, Masao Edagawa, Masayuki Maeda, Tetsuya Shimizu, Masaki Hara, Toshio Onitsuka.   

Abstract

OBJECTIVE: Because it is difficult to predict the behavior of thymomas on the basis of morphology alone, other methods for determining tumor aggressiveness must be explored. This study investigated the correlation between angiogenic grade and invasiveness in thymic epithelial tumors.
METHODS: Immunohistochemical studies of 46 surgically resected thymic epithelial tumors (18 noninvasive thymomas, 20 invasive thymomas, and 8 thymic carcinomas) were conducted. To highlight the microvessels, we used a specific monoclonal antibody against factor VIII. Expression of vascular endothelial growth factor and basic fibroblast growth factor was determined by using polyclonal antibodies.
RESULTS: Mean microvessel density readings for noninvasive thymomas, invasive thymomas, and thymic carcinomas were 4.6 +/- 3.2, 12.4 +/- 7.5, and 34.4 +/- 16.7, respectively. Stages I, II, III, and IV of thymoma had microvessel density readings of 4.6 +/- 3.2, 8.5 +/- 4.3, 13.8 +/- 7.7, and 22.0 +/- 6.8, respectively. These findings suggest a significant correlation between microvessel density and tumor invasiveness. Vascular endothelial growth factor expression in noninvasive thymomas, invasive thymomas, and thymic carcinomas was present in 1 (5.6%) of 18, 11 (55.0%) of 20, and 5 (62.5%) of 8 patients, respectively, thereby indicating a distinct association between vascular endothelial growth factor expression and increased microvessel density. Basic fibroblast growth factor expression was present in only 8 patients.
CONCLUSIONS: In patients with thymic epithelial tumors, there appears to be a significant correlation between tumor angiogenesis and invasiveness. Furthermore, our data suggests that this angiogenesis in thymic epithelial tumors might be, at least in part, dependent on vascular endothelial growth factor expression.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12202865     DOI: 10.1067/mtc.2002.124389

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  16 in total

1.  Prognostic value of immunohistochemical markers in malignant thymic epithelial tumors.

Authors:  Priska Leisibach; Didier Schneiter; Alex Soltermann; Yoshi Yamada; Walter Weder; Wolfgang Jungraithmayr
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

2.  Platelet-derived growth factor and platelet-derived growth factor receptor-α expression in the normal human thymus and thymoma.

Authors:  Anca Maria Cimpean; Raluca Ceauşu; Svetlana Encică; Pusa Nela Gaje; Domenico Ribatti; Marius Raica
Journal:  Int J Exp Pathol       Date:  2011-06-07       Impact factor: 1.925

Review 3.  Thymic malignancies: from clinical management to targeted therapies.

Authors:  Ronan J Kelly; Iacopo Petrini; Arun Rajan; Yisong Wang; Giuseppe Giaccone
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

4.  Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial.

Authors:  Anish Thomas; Arun Rajan; Arlene Berman; Yusuke Tomita; Christina Brzezniak; Min-Jung Lee; Sunmin Lee; Alexander Ling; Aaron J Spittler; Corey A Carter; Udayan Guha; Yisong Wang; Eva Szabo; Paul Meltzer; Seth M Steinberg; Jane B Trepel; Patrick J Loehrer; Giuseppe Giaccone
Journal:  Lancet Oncol       Date:  2015-01-13       Impact factor: 41.316

5.  Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.

Authors:  Thomas Neuhaus; Joachim Luyken
Journal:  Target Oncol       Date:  2012-10-23       Impact factor: 4.493

6.  Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.

Authors:  Xiao-Feng Li; Qiang Chen; Wei-Xian Huang; Yun-Bin Ye
Journal:  Med Oncol       Date:  2008-10-10       Impact factor: 3.064

7.  Clinical and immunohistochemical study of eight cases with thymic carcinoma.

Authors:  Masaki Tomita; Yasunori Matsuzaki; Masao Edagawa; Masayuki Maeda; Tetsuya Shimizu; Masaki Hara; Toshio Onitsuka
Journal:  BMC Surg       Date:  2002-05-23       Impact factor: 2.102

8.  Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E.

Authors:  Chiara Catania; Fabio Conforti; Gianluca Spitaleri; Massimo Barberis; Lorenzo Preda; Cristina Noberasco; Chiara Lazzari; Francesca Toffalorio; Filippo de Marinis; Michela Manzotti; Tommaso Martino De Pas
Journal:  Onco Targets Ther       Date:  2014-05-08       Impact factor: 4.147

9.  Predicting subtypes of thymic epithelial tumors using CT: new perspective based on a comprehensive analysis of 216 patients.

Authors:  Yu-Chuan Hu; Lang Wu; Lin-Feng Yan; Wen Wang; Shu-Mei Wang; Bao-Ying Chen; Gang-Feng Li; Bei Zhang; Guang-Bin Cui
Journal:  Sci Rep       Date:  2014-11-10       Impact factor: 4.379

10.  Intravoxel incoherent motion diffusion-weighted MR imaging parameters predict pathological classification in thymic epithelial tumors.

Authors:  Gang-Feng Li; Shi-Jun Duan; Lin-Feng Yan; Wen Wang; Yong Jing; Wei-Qiang Yan; Qian Sun; Shu-Mei Wang; Hai-Yan Nan; Tian-Yong Xu; Dan-Dan Zheng; Yu-Chuan Hu; Guang-Bin Cui
Journal:  Oncotarget       Date:  2017-07-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.